(Q30420274)

21 June 2017

title

A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. (English)

1 reference

21 June 2017

0 references

0 references

1 reference

Maria Luisa Moro

1

0 references

author name string

Lucia Nobilio

2

1 reference

21 June 2017

Claudio Voci

3

1 reference

21 June 2017

Simona Di Mario

4

1 reference

21 June 2017

Silvia Candela

5

1 reference

21 June 2017

Nicola Magrini

6

1 reference

21 June 2017

SaFoH1N1 working group

7

1 reference

21 June 2017

language of work or name

English

0 references

publication date

10 August 2012

1 reference

21 June 2017

1 reference

21 June 2017

volume

31

1 reference

21 June 2017

issue

10

1 reference

21 June 2017

page(s)

1438-1446

1 reference

Evolutionary genomics of the pandemic 2009 H1N1 influenza viruses (pH1N 1v).

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Critically Ill patients with 2009 influenza A(H1N1) in Mexico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

An early (3-6 weeks) active surveillance study to assess the safety of pandemic influenza vaccine Focetria in a province of Emilia-Romagna region, Italy - part one.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Predictors and outcomes of limited resection for early-stage non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Influenza: epidemiology, clinical features, therapy, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Update on avian influenza A (H5N1) virus infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Effectiveness and safety of the A-H1N1 vaccine in children: a hospital-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.07.090

10.1016/J.VACCINE.2012.07.090

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference